575 related articles for article (PubMed ID: 28092414)
1. DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness.
Hectors SJ; Besa C; Wagner M; Jajamovich GH; Haines GK; Lewis S; Tewari A; Rastinehad A; Huang W; Taouli B
J Magn Reson Imaging; 2017 Sep; 46(3):837-849. PubMed ID: 28092414
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced (DCE) MR imaging: the role of qualitative and quantitative parameters for evaluating prostate tumors stratified by Gleason score and PI-RADS v2.
Afshari Mirak S; Mohammadian Bajgiran A; Sung K; Asvadi NH; Markovic D; Felker ER; Lu D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2020 Jul; 45(7):2225-2234. PubMed ID: 31549211
[TBL] [Abstract][Full Text] [Related]
3. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
4. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
[TBL] [Abstract][Full Text] [Related]
5. Luminal Water Imaging: Comparison With Diffusion-Weighted Imaging (DWI) and PI-RADS for Characterization of Prostate Cancer Aggressiveness.
Hectors SJ; Said D; Gnerre J; Tewari A; Taouli B
J Magn Reson Imaging; 2020 Jul; 52(1):271-279. PubMed ID: 31961049
[TBL] [Abstract][Full Text] [Related]
6. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
[TBL] [Abstract][Full Text] [Related]
7. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
8. Differential diagnosis of prostate cancer and noncancerous tissue in the peripheral zone and central gland using the quantitative parameters of DCE-MRI: A meta-analysis.
Gao P; Shi C; Zhao L; Zhou Q; Luo L
Medicine (Baltimore); 2016 Dec; 95(52):e5715. PubMed ID: 28033274
[TBL] [Abstract][Full Text] [Related]
9. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Dispersion MRI for Improved Prostate Cancer Diagnosis in a Multicenter Study.
Turco S; Lavini C; Heijmink S; Barentsz J; Wijkstra H; Mischi M
AJR Am J Roentgenol; 2018 Nov; 211(5):W242-W251. PubMed ID: 30346837
[TBL] [Abstract][Full Text] [Related]
11. DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience.
Jajamovich GH; Huang W; Besa C; Li X; Afzal A; Dyvorne HA; Taouli B
MAGMA; 2016 Feb; 29(1):49-58. PubMed ID: 26646522
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced MRI of the prostate: An intraindividual assessment of the effect of temporal resolution on qualitative detection and quantitative analysis of histopathologically proven prostate cancer.
Ream JM; Doshi AM; Dunst D; Parikh N; Kong MX; Babb JS; Taneja SS; Rosenkrantz AB
J Magn Reson Imaging; 2017 May; 45(5):1464-1475. PubMed ID: 27649481
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI in PI-RADS category 3 peripheral zone lesions: preliminary study evaluating DCE-MRI as an imaging biomarker for detection of clinically significant prostate cancers.
Abreu-Gomez J; Lim C; Cron GO; Krishna S; Sadoughi N; Schieda N
Abdom Radiol (NY); 2021 Sep; 46(9):4370-4380. PubMed ID: 33818626
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of dynamic
Tau N; Berlin A; Yeung I; Halankar J; Murphy G; Jhaveri KS; Ghai S; Metser U
Br J Radiol; 2019 Feb; 92(1094):20180568. PubMed ID: 30383459
[TBL] [Abstract][Full Text] [Related]
15. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
Cristel G; Esposito A; Damascelli A; Briganti A; Ambrosi A; Brembilla G; Brunetti L; Antunes S; Freschi M; Montorsi F; Del Maschio A; De Cobelli F
Eur J Radiol; 2019 Sep; 118():51-57. PubMed ID: 31439258
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
[TBL] [Abstract][Full Text] [Related]
18. A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
Baur ADJ; Schwabe J; Rogasch J; Maxeiner A; Penzkofer T; Stephan C; Rudl M; Hamm B; Jung EM; Fischer T
Eur Radiol; 2018 May; 28(5):1949-1960. PubMed ID: 29238867
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
20. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T.
Vos EK; Litjens GJ; Kobus T; Hambrock T; Hulsbergen-van de Kaa CA; Barentsz JO; Huisman HJ; Scheenen TW
Eur Urol; 2013 Sep; 64(3):448-55. PubMed ID: 23751135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
